euro adhoc: Intercell AG / Joint Ventures/Cooperation/Collaboration / Vaccine formulated with Intercell's adjuvant IC31® part of a broader collaboration to fight Tuberculosis

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

14.02.2008

» TB-vaccine collaboration between Sanofi Pasteur and Statens Serum
Institut (SSI) including Intercell´s adjuvant IC31® » World-leading
Tuberculosis research and vaccine development aiming to make a new
TB vaccine widely available in shortest possible time

Intercell AG today announced that a Tuberculosis vaccine, which is
currently tested in clinical trials and which contains antigens
discovered by Statens Serum Institut formulated with Intercell's
innovative adjuvant IC31®, will be further developed in a partnership
between SSI and Sanofi Pasteur.

SSI and Intercell will continue their world-leading collaboration in
the field of Tuberculosis research and vaccine development with
Intercell´s proprietary adjuvant IC31®, and by the involvement of
Sanofi Pasteur extend the activities into more advanced phases aiming
to make a new TB vaccine widely available in shortest possible time.

The collaboration with Aeras Global TB Vaccine Foundation in the TB
vaccine field will continue and together the parties represent the
extensive range of technology and expertise necessary to solve this
complex global health problem.

"We are very happy that Sanofi Pasteur is now contributing all its
outstanding vaccine expertise to this very promising tuberculosis
vaccine program" comments Intercell's Chief Executive Officer Gerd
Zettlmeissl. "The preclinical and the Phase I clinical studies
performed so far have impressively proven that our novel adjuvant
IC31® will play an important role in this combined vaccine approach."

Financial details are not disclosed.

About Tuberculosis (TB) TB causes the death of more than 1.5 million
people every year and one-third of the world´s population is infected
by the bacteria "Mycobacterium tuberculosis" which makes this disease
one of the most severe global health problems. The existing Bacillus
Calmette-Guérin vaccine (BCG) vaccine is a live vaccine that, when
given to newborns, provides good protection against TB for 10-15
years. However, when the protective effect decreases, yet another BCG
vaccination does not provide sufficient TB protection. Therefore, a
new type of TB vaccine is needed to address the need of TB protection
in the adult population.

About IC31® Vaccines, based on antigens alone, are not sufficient to
maximize protection. Adjuvants are needed to educate the immune
system to recognize and eliminate the pathogens efficiently. IC31® is
an adjuvant that induces T-cell and B-cell responses by using a
unique synthetic formulation which combines the immunostimulating
properties of an anti-microbial peptide, KLK, and an
immunostimulatory oligodeoxynucleotide, ODN1a. The two component
solution can be simply mixed with antigens; no conjugation is
required. Intercell currently uses IC31® in collaborations with a
number of global vaccine companies and biotech companies.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Dr. Werner Lanthaler

Chief Financial Officer

+43 1 20620-120

wlanthaler@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market